Safety, tolerability, and antibody response of active A尾 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

详细信息	查看全文 | 推荐本文 |

• 作者：Prof Bengt Winblad ; MD^a ; ^{bengt.winblad@ki.se} ; Niels Andreasen ; MD^a ; Prof Lennart Minthon ; MD^b ; Annette Floesser ; MSc^c ; Georges Imbert ; PhD^c ; Thomas Dumortier ; MSc^d ; R Paul Maguire ; PhD^c ; Kaj Blennow ; MD^e ; Joens Lundmark ; MD^f ; Matthias Staufenbiel ; PhD^c ; Prof Jean-Marc Orgogozo ; MD^g ; Ana Graf ; MD^d
• 刊名：Lancet Neurology
• 出版年：2012
• 期刊代码：300_14744422
• 类别：med
• 出版时间：July, 2012
• 卷：11
• 期：7
• 页码：597-604
• 文件大小：606 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

Immunotherapy targeting the amyloid 尾 (A尾) peptide is a potential strategy to slow the progression of Alzheimer's disease. We aimed to assess the safety and tolerability of CAD106, a novel active A尾 immunotherapy for patients with Alzheimer's disease, designed to induce N-terminal A尾-specific antibodies without an A尾-specific T-cell response.

Methods

We did a phase 1, double-blind, placebo-controlled, 52-week study in two centres in Sweden. Participants, aged 50-80 years, with mild-to-moderate Alzheimer's disease were entered into one of two cohorts according to time of study entry and then randomly allocated (by use of a computer-generated randomisation sequence) to receive either CAD106 or placebo (4:1; cohort one received CAD106 50 渭g or placebo, cohort two received CAD106 150 渭g or placebo). Each patient received three subcutaneous injections. All patients, caregivers, and investigators were masked to treatment allocation throughout the study. Primary objectives were to assess the safety and tolerability of CAD106 and to identify the A尾-specific antibody response. Safety assessment was done by recording of all adverse events, assessment of MRI scans, physical and neurological examinations, vital signs, electrocardiography, electroencephalography, and laboratory analysis of blood and CSF. Patients with A尾-IgG serum titres higher than 16 units at least once during the study were classified as responders. This study is registered with , number .

Findings

Between August, 2005, and March, 2007, we randomly allocated 31 patients into cohort one (24 patients to CAD106 treatment and seven to placebo) and 27 patients into cohort two (22 patients to CAD106 treatment and five to placebo). 56 of 58 patients reported adverse events. In cohort one, nasopharyngitis was the most commonly reported adverse event (10 of 24 CAD106-treated patients). In cohort two, injection site erythema was the most commonly reported adverse event (14 of 22 CAD106-treated patients). Overall, nine patients reported serious adverse events鈥攏one was thought to be related to the study drug. We recorded no clinical or subclinical cases of meningoencephalitis. 16 of 24 (67%) CAD106-treated patients in cohort one and 18 of 22 (82%) in cohort two developed A尾 antibody response meeting pre-specified responder threshold. One of 12 placebo-treated patients (8%) had A尾-IgG concentrations that qualified them as a responder.

Interpretation

Our findings suggest that CAD106 has a favourable safety profile and acceptable antibody response in patients with Alzheimer's disease. Larger trials with additional dose investigations are needed to confirm the safety and establish the efficacy of CAD106.

Funding

Novartis Pharma AG.